A retrospective cohort study using data from 103 healthcare organizations compared 454 pulmonary arterial hypertension patients receiving sotatercept to 963.386 pulmonary arterial hypertension patients not receiving sotatercept. After propensity score matching to balance baseline characteristics, 346 patients per group were analyzed over an average follow-up of approximately 6-8 months. The sotatercept group demonstrated dramatically lower

A very interesting article by Prof. Werner Seeger recounts the discovery and development of inhaled prostanoids for pulmonary hypertension at the Giessen Pulmonary Hypertension center (Germany) in the late 1980s-1990s (§). Initially researching acute lung injury/Acute Respiratory Distress Syndrome (ARDS), researchers at Giessen observed that while intravenous vasodilators worsened ventilation/perfusion mismatch, aerosolized prostacyclin (PGI2) reduced

Parenteral prostacyclin therapy remains the cornerstone for high-risk pulmonary arterial hypertension (PAH) patients but is limited by complications and reduced quality of life. A case series of eight high-risk patients demonstrated that adding sotatercept successfully enabled transition from intravenous to oral prostacyclin therapy. All patients received background dual therapy with endothelin receptor antagonists and phosphodiesterase-5

A network meta-analysis conducted by researchers at the Cleveland Clinic Abu Dhabi, published in the October 2025 edition of Frontiers in Medicine, compared the efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension (PAH) by synthesizing data from 32 studies, comprising 24 randomised controlled trials, three open-label trials,and five cohort studies, with a cumulative

The phase 3 HYPERION trial on sotatercept enrolled 320 adults with newly diagnosed pulmonary arterial hypertension (within 1 year of diagnosis) at intermediate or high risk who were already on double or triple background therapy. Patients were randomized to receive add-on subcutaneous sotatercept or placebo every 21 days. The trial stopped early due to compelling

Despite historical use, the role of anticoagulant therapy in the management of pulmonary arterial hypertension (PAH) remains uncertain, as existing epidemiologic studies have produced conflicting results. The goal of a study whose findings were published in the Journal of the American College of Cardiology on September 30, 2025, was to examine the association between anticoagulant

  Pulmonary arterial hypertension (PAH) happens when the blood vessels in the lungs become too narrow and stiff. This raises pressure in the lungs and puts strain on the heart. In a collaborative study, scientists from Inserm and Université Paris-Saclay in France, together with researchers from the Institute for Lung Health (ILH) in Germany, discovered